Equities

Vivimed Labs Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
VIVIMEDLAB:NSI

Vivimed Labs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)7.04
  • Today's Change-0.31 / -4.22%
  • Shares traded297.34k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Feb 16 2026 08:29 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Vivimed Labs Limited is an India-based company engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. The Company is primarily engaged in Pharma segment. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. Its manufacturing facilities are equipped to deliver a range of dosage delivery formats that include capsules, tablets, syrups & liquids, sprays & ointments.

  • Revenue in INR (TTM)1.04bn
  • Net income in INR-243.69m
  • Incorporated1988
  • Employees586.00
  • Location
    Vivimed Labs LtdNorth End, Road No. 2,, Banjara Hills,HYDERABAD 500034IndiaIND
  • Phone+91 4 066086608
  • Fax+91 4 066086699
  • Websitehttps://www.vivimedlabs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lasa Supergenerics Ltd952.91m-361.68m447.40m66.00--0.7941--0.4695-7.57-7.5719.5811.250.87056.0636.0814,437,960.00-33.04-6.42-46.76-8.5422.2828.58-37.96-8.050.5203-14.700.1152--36.53-3.1632.09------
Vilin Bio Med Ltd199.81m2.51m473.60m--188.202.04133.302.370.18040.180414.3416.640.68453.653.25--0.85921.811.082.706.6021.721.262.714.161.190.0193---6.30-2.5137.626.62130.50--
Mangalam Drugs and Organics Ltd2.38bn-309.21m517.43m414.00------0.217-19.53-19.53150.57--------5,758,911.00--2.90--5.3439.1529.02-12.972.46---0.9827-----13.662.42174.27-4.0223.85--
Biofil Chemicals and Pharmaceuticals Ltd425.20m28.59m584.39m26.0020.492.7418.421.371.751.7525.8713.090.87317.841.2816,353,690.005.872.1314.164.335.228.636.722.331.338.280.0009---16.572.38-21.36-14.31-13.50--
Vineet Laboratories Ltd570.37m-166.97m590.98m----2.36--1.04-15.30-15.3052.0813.020.57851.014.23---16.94-1.82-54.66-5.754.8619.76-29.27-1.090.1186-3.060.7505---50.20---2,065.83------
Vivimed Labs Ltd1.04bn-243.69m614.39m586.00------0.5901-2.93-2.9312.54-5.780.11150.88321.171,776,860.00-2.60-9.00-4.80-13.9151.9327.65-23.29-35.170.6624-5.541.14---22.00-35.7129.67---47.43--
Onyx Biotec Ltd663.87m10.68m643.69m--30.501.1815.540.96961.161.1644.5030.180.78143.902.95--1.26--1.90--29.72--1.61--1.352.130.2233--15.26--36.31------
Accretion Pharmaceuticals Ltd573.76m67.94m761.45m121.0011.214.9810.061.336.116.1151.6213.75------4,741,835.00--------30.44--11.84--0.5578.300.4799--70.43--75.30------
Data as of Feb 16 2026. Currency figures normalised to Vivimed Labs Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.